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OBJECTIVES In this study, we examined the effects of long-term therapy with bosentan on the progression
of LV dysfunction and remodeling in dogs with moderate HF.
BACKGROUND Acute intravenous administration of bosentan, a mixed endothelin-1 type A and type B
receptor antagonist, was shown to improve left ventricular (LV) function in patients and dogs
with heart failure (HF).
METHODS Left ventricular dysfunction was induced by multiple, sequential intracoronary microembo-
lizations in 14 dogs. Embolizations were discontinued when LV ejection fraction (EF) was
between 30% and 40%. Dogs were randomized to three months of therapy with bosentan
(30 mg/kg twice daily, n 5 7) or no therapy at all (control, n 5 7).
RESULTS In untreated dogs, EF decreased from 35 6 1% before initiating therapy to 29 6 1% at the
end of three months of therapy (p 5 0.001), and LV end-diastolic volume (EDV) and
end-systolic volume (ESV) increased (EDV: 71 6 3 vs. 84 6 8 ml, p 5 0.08; ESV: 46 6 2
vs. 60 6 6 ml, p 5 0.03). By contrast, in dogs treated with bosentan, EF tended to increase
from 34 6 2% before initiating therapy to 39 6 1% at the end of three months of therapy
(p 5 0.06), and EDV and ESV decreased (EDV: 75 6 3 vs. 71 6 4 ml, p 5 0.05; ESV: 48 6
2 vs. 43 6 3 ml, p 5 0.01). Furthermore, compared with untreated dogs, dogs treated with
bosentan showed significantly less LV cardiomyocyte hypertrophy and LV volume fraction of
interstitial fibrosis.
CONCLUSIONS In dogs with moderate HF, long-term therapy with bosentan prevents the progression of LV
dysfunction and attenuates LV chamber remodeling. The findings support the use of mixed
endothelin-1 receptor antagonists as adjuncts to the long-term treatment of HF. (J Am Coll
Cardiol 2000;35:222–9) © 1999 by the American College of Cardiology
Endothelin (ET) is a vascular endothelial cell–derived
vasoconstrictor peptide that functions as a circulating hor-
mone as well as a paracrine factor in regulating vascular tone
(1–3). Endothelin-1 (ET-1), one of three isoforms of
endothelin (4), has been demonstrated to play an active role
in the pathophysiology of heart failure (HF). The observa-
tion that ET-1 is elevated in HF and that ET-1 receptor
antagonists can decrease both systemic and pulmonary
pressures in patients and animal models of HF provides
further support for its functional importance (5–8). In
addition to its vasoconstrictor effects (4,9,10), ET-1 has
been shown to augment the inotropic function of the heart
(11–14). Endogenous ET-1 has also been shown to play a
role in stimulating cardiomyocyte hypertrophy (15–17), to
promote collagen turnover in cardiac fibroblasts (18) and to
induce both myocardial ischemia and edema (19). All of
these pathophysiologic effects suggest that ET-1 may po-
tentially play a key role in the progression of left ventricular
(LV) dysfunction and chamber remodeling that are charac-
teristic features of HF.
The extent of plasma elevation of ET-1 in patients with
HF has been shown to correlate with the magnitude of
alterations in cardiac hemodynamic variables and New York
Heart Association functional class (5). Plasma ET concen-
tration has also been shown to be strongly related to
mortality after acute myocardial infarction (14). With these
associations in mind, and in view of endothelin’s well-
known potent vasoconstrictor properties, ET-1 receptor
antagonists have been suggested to have potential therapeu-
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tic benefit in HF by decreasing systemic vascular resistance
(20–27), a hallmark of HF. The development of bosentan
(28), a mixed endothelin-1 type A (ETA) and type B (ETB)
receptor antagonist, provided an opportunity to study the
effects of ET-1 blockade in chronic HF. In earlier studies,
intravenous administration of bosentan was shown to de-
crease systemic vascular resistance and increase cardiac
output both in patients with congestive HF (29,30) and in
a canine model of chronic HF (22). The present study was
designed to determine the effect of early, long-term therapy
with bosentan on the progression of LV dysfunction and
chamber remodeling in dogs with moderate HF induced by
multiple, sequential intracoronary embolization of micro-
spheres.
METHODS
Animal model. The canine model of chronic HF used in
the present study was previously described in detail (31). In
this experimental preparation, chronic LV dysfunction is
induced by multiple, sequential intracoronary embolizations
with polystyrene Latex microspheres (70 to 102 mm in
diameter), which results in loss of viable myocardium as
seen in myocardial infarction. The model manifests many of
the sequelae of HF seen in humans, including marked and
sustained depression of LV systolic and diastolic function,
reduced cardiac output, increased LV filling pressures,
increasing systemic vascular resistance, enhanced activity of
the sympathetic nervous system and increased plasma con-
centration of ET-1 (22,31). In the present study, 14 healthy
mongrel dogs, weighing between 18 and 31 kg, underwent
serial coronary microembolizations to induce HF. Emboli-
zations were performed one to three weeks apart and were
discontinued when the LV ejection fraction (EF), deter-
mined angiographically, was between 30% and 40%. Mi-
croembolizations were performed during cardiac catheter-
ization under general anesthesia and with sterile conditions.
The anesthesia regimen used in the present study consisted
of a combination of intravenous injection of oxymorphone
(0.22 mg/kg body weight), diazepam (0.17 mg/kg) and
sodium pentobarbital (150 to 250 mg to effect). This
anesthesia regimen was previously shown to have no effect
on global LV function (32). Each dog underwent an average
of eight coronary microembolization procedures. Emboliza-
tions were performed one to three weeks apart and were
discontinued when LVEF was between 30% and 40%.
Study protocol. Two weeks after the last coronary micro-
embolization, all dogs underwent a prerandomization left
and right heart catheterization (pretreatment). The two-
week period was allowed to ensure that all infarctions
produced by the last microembolization session were com-
pletely healed. One day after the cardiac catheterization,
dogs were randomized to three months of oral monotherapy
with bosentan (30 mg/kg twice daily, n 5 7) or no
treatment at all (control arm, n 5 7). No other drugs were
used in any of the study arms during the three months of
follow-up. After a final hemodynamic and angiographic
study performed at the end of three months of therapy
(post-treatment), the dogs were killed, and the heart was
removed for histologic examination. The study was ap-
proved by the Henry Ford Hospital’s Care of Experimental
Animals Committee and conformed to the “Position of the
American Heart Association on Research Animal Use,”
adopted by the Association in November 1984, and to the
guiding principles of the American Physiological Society.
Hemodynamic and angiographic measurements. In all
study dogs, hemodynamic and angiographic measurements
were obtained during left and right heart catheterizations.
Aortic and LV pressures were measured with catheter-
tipped micromanometers (Millar Instruments, Houston,
Texas). Left ventricular peak rate of change in pressure
during isovolumic contraction (peak rate of rise in LV
pressure [1dP/dt]) and isovolumic relaxation (peak 2dP/
dt), as well as LV end-diastolic pressure, were measured
from the phasic LV pressure waveform. Cardiac output was
measured in duplicate using the thermodilution method by
means of a Swan-Ganz catheter. Cardiac index was calcu-
lated as the ratio of cardiac output to body surface area.
Systemic vascular resistance was calculated as the difference
between mean aortic pressure and mean right atrial pres-
sure 3 80/cardiac output (32). Left ventriculograms were
obtained during each cardiac catheterization procedure after
completion of the hemodynamic measurements with the
dog placed on its right side. Ventriculograms were recorded
on 35-mm cine film at 30 frames/s during the injection of
20 ml of contrast material (Reno-M-60, Squibb, Princeton,
New Jersey). Correction for image magnification was made
using a radiopaque calibrated scale placed at the level of the
left ventricle. Left ventricular end-systolic volume (ESV)
and end-diastolic volume (EDV) were calculated from
angiographic silhouettes using the area–length method (33).
Ejection fraction was calculated as ([EDV 2 ESV]/
EDV) 3 100. Extrasystolic and postextrasystolic beats were
excluded from all angiographic analyses. Venous blood
samples were obtained from conscious dogs one day before
the cardiac catheterization for evaluation of plasma concen-
tration of norepinephrine. To minimize possible variations,
blood samples were always obtained between 8:00 and 10:00
AM. Plasma norepinephrine concentration was measured
Abbreviations and Acronyms
EDV 5 end-diastolic volume
EF 5 ejection fraction
ESV 5 end-systolic volume
ET 5 endothelin
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HF 5 heart failure
LV 5 left ventricular
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using aluminum oxide absorption by high performance
liquid chromatography.
Histologic and morphometric assessments. At the end of
three months of therapy and immediately after the final
hemodynamic and angiographic evaluation, each dog’s chest
was opened through a left thoracotomy, the pericardium
was opened and the heart was rapidly removed and placed in
ice-cold cardioplegia solution. From each heart, a transverse
slice, ;3 mm thick, was obtained from the LV at the
mid-ventricular level. Transmural tissue blocks were ob-
tained from the free wall segment of the slice, mounted on
cork using Tissue-Tek embedding medium (Miles Inc.,
Mishawaka, Indiana) and rapidly frozen in isopentane
precooled in liquid nitrogen and stored at 270°C until used.
Cryostat sections, ;8 mm thick, were prepared from each
block and stained with fluorescein-labeled peanut agglutinin
(Vector Laboratories Inc., Burlingame, California) after
pretreatment with 3.3 U/ml neuroaminidase type V (Sigma
Chemical Co., St. Louis, Missouri) to delineate the myocyte
border and the interstitial space, including capillaries as
previously described (34). Sections were double-stained
with rhodamine-labeled Griffonia simplicifolia lectin I to
identify capillaries. Ten radially oriented microscopic fields,
magnification 3 100 (objective 40 and ocular 2.5), were
selected at random from each section and photographed
using 35-mm color film. Fields containing scar tissue
(infarcts) were excluded. Images were projected with a
photo magnifier, and the cross-sectional area of each myo-
cyte was measured using computer-based planimetry. An
average myocyte cross-sectional area was calculated for each
dog using data obtained from all fields. The total surface
area occupied by interstitial space and the total surface area
occupied by capillaries were measured from each randomly
selected field using computer-based video densitometry
(JAVA, Jandel Scientific, Corte Madera, California). The
volume fraction of interstitial collagen (interstitial fibrosis)
was calculated as the percent total surface area occupied by
interstitial space, minus the percent total area occupied by
capillaries (34). An average volume fraction of interstitial
fibrosis was calculated for each dog using data obtained
from all fields. For comparison purposes, measurements of
myocyte cross-sectional area and volume fraction of inter-
stitial fibrosis were made using identical techniques in LV
tissue sections obtained from seven normal dogs.
Data analysis. To ensure that all study measures were
similar at baseline, before any embolizations, and at the time
of randomization before initiation of therapy, comparisons
were made between the two study groups. For these
comparisons, a t statistic for two means was used, and a
p value #0.05 was considered significant. Intragroup com-
parisons between pretreatment and post-treatment mea-
sures were made using the Student paired t test, with p ,
0.05 considered significant. To assess the treatment effect,
the change in each measure from pretreatment to post-
treatment was calculated for each of the two study arms. To
determine whether significant differences in change were
present between the two groups, a t statistic for two means
was used, with p # 0.05 considered significant. Repeated
measures analysis of variance was also used to test for time
by treatment interaction. All data are reported as the mean
value 6 SEM.
RESULTS
At baseline, all dogs entered into the study had hemody-
namic data and angiographic findings that were within the
normal limits for mongrel dogs in our laboratory. Baseline
data for both study groups are shown in Table 1. There were
no significant differences in any of the variables between
dogs that were subsequently randomized to no treatment
and dogs randomized to active treatment with bosentan.
Furthermore, there were no significant differences in any the
study variables measured just before randomization between
the two study groups. These data are shown in Tables 2
and 3.
Progression of LV dysfunction in untreated dogs. The
pretreatment and post-treatment hemodynamic, angio-
graphic and neurohumoral measures are shown in Table 2.
As expected, EF decreased significantly during the three-
month follow-up period (Table 2, Fig. 1). This was accom-
panied by an increase in both ESV and EDV, although the
increase in EDV did not reach statistical significance (Fig.
2). Lack of therapy was also associated with a decrease of
peak 1dP/dt, a decrease in cardiac index and an increase in
plasma norepinephrine concentration. Systemic vascular
resistance tended to increase, and LV end-diastolic pressure
remained unchanged (Table 2).
Effects of monotherapy with bosentan. The pretreatment
and post-treatment hemodynamic, angiographic and neu-
rohumoral measures are shown in Table 3. In dogs treated
Table 1. Baseline Hemodynamic, Angiographic and Plasma
Norepinephrine Measurements
Control
Group
Bosentan
Group
HR (beats/min) 82 6 5 77 6 3
Mean AoP (mm Hg) 115 6 5 119 6 3
LV EDP (mm Hg) 9 6 1 9 6 1
Peak 1dP/dt (mm Hg/s) 2,239 6 107 2,169 6 185
Peak 2dP/dt (mm Hg/s) 2,777 6 129 2,623 6 293
CI (liters/min per m2) 3.1 6 0.4 2.7 6 0.2
SVR (dyneszszcm25) 3,873 6 609 4,479 6 375
LV EDV (ml) 63 6 4 60 6 2
LV ESV (ml) 30 6 1 30 6 2
LV EF (%) 51 6 2 51 6 1
PNE (pg/ml) 231 6 31 277 6 50
Data are presented as the mean value 6 SEM.
AoP 5 aortic pressure; CI 5 cardiac index; dP/dt 5 rate of change of left
ventricular pressure during isovolumic contraction (1) and relaxation (2); EDP 5
end-diastolic pressure; EDV 5 end-diastolic volume; EF 5 ejection fraction; ESV 5
end-systolic volume; HR 5 heart rate; LV 5 left ventricular; PNE 5 plasma
norepinephrine concentration; SVR 5 systemic vascular resistance.
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with bosentan, heart rate and mean aortic pressure were
unchanged between pretreatment and post-treatment (Ta-
ble 3). Left ventricular EF tended to increase but did not
reach statistical significance, whereas both ESV and EDV
decreased significantly (Fig. 1 and 2, Tables 2 and 3). Three
months of treatment with bosentan maintained peak
1dP/dt and significantly increased peak 2dP/dt. Cardiac
index increased significantly, and systemic vascular resis-
tance decreased significantly (Table 3). Left ventricular
end-diastolic pressure and circulating levels of plasma nor-
epinephrine tended to decrease but did not reach statistical
difference (Table 3).
Comparisons of treatment effect. In the post-treatment
analysis, the two treatment arms were compared. The
changes in hemodynamic, angiographic and neurohumoral
measures between untreated control dogs and dogs treated
with bosentan are shown in Table 4. Compared with no
treatment, bosentan significantly increased the LVEF and
significantly reduced ESV and EDV (Fig. 3). With bosen-
tan, cardiac index, peak 1dP/dt and peak 2dP/dt increased
significantly, and systemic vascular resistance and plasma
norepinephrine concentration decreased significantly as
compared with no treatment. Left ventricular end-diastolic
pressure tended to be lower and heart rate and mean arterial
pressure were unchanged with bosentan as compared with
no treatment (Table 4). The p values for repeated measures
interaction are shown in Table 4.
Histomorphometric findings are shown in Table 5. Car-
diac myocyte cross-sectional area and volume fraction of
interstitial fibrosis were both significantly higher in un-
treated dogs with HF than in normal dogs. Treatment with
bosentan modified these processes. Average cardiomyocyte
cross-sectional area was significantly smaller in dogs treated
with bosentan than in untreated control dogs. Similarly,
volume fraction of interstitial fibrosis was significantly lower in
dogs treated with bosentan than in control dogs (Table 5).
Table 2. Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained
Before Randomization and After Three Months of Follow-Up
Control Group (Untreated)
Prerandomization Follow-Up p Value
HR (beats/min) 79 6 6 73 6 2 0.19
Mean AoP (mm Hg) 106 6 3 107 6 6 0.74
LV EDP (mm Hg) 15 6 1 15 6 1 0.72
Peak 1dP/dt (mm Hg/s) 1,814 6 72 1,579 6 94 0.04
Peak 2dP/dt (mm Hg/s) 1,810 6 113 1,591 6 94 0.12
CI (liters/min per m2) 2.3 6 0.2 2.0 6 0.2 0.02
SVR (dyneszszcm25) 4,217 6 476 5,124 6 828 0.13
LV EDV (ml) 71 6 3 84 6 8 0.08
LV ESV (ml) 46 6 2 60 6 6 0.03
LV EF (%) 35 6 1 29 6 1 0.001
PNE (pg/ml) 300 6 32 418 6 46 0.006
Data are presented as the mean value 6 SEM.
Abbreviations are the same as in Table 1.
Table 3. Hemodynamic, Angiographic and Plasma Norepinephrine Measurements Obtained
Before Initiating Therapy and After Three Months of Therapy
Bosentan (30 mg/kg twice daily)
Pretreatment Post-treatment p Value
HR (beats/min) 76 6 4 80 6 6 0.39
Mean AoP (mm Hg) 105 6 4 104 6 5 0.78
LV EDP (mm Hg) 15 6 2 12 6 2 0.08
Peak 1dP/dt (mm Hg/s) 1,934 6 107 2,034 6 162 0.40
Peak 2dP/dt (mm Hg/s) 1,887 6 57 2,380 6 164 0.04
CI (liters/min per m2) 2.3 6 0.1 2.9 6 0.3 0.04
SVR (dyneszszcm25) 4,321 6 98 3,410 6 276 0.01
LV EDV (ml) 75 6 3 71 6 4 0.05
LV ESV (ml) 48 6 2 43 6 3 0.01
LV EF (%) 34 6 2 39 6 1 0.06
PNE (pg/ml) 327 6 69 262 6 38 0.74
Data are presented as the mean value 6 SEM.
Abbreviations as in Table 1.
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DISCUSSION
This study demonstrates that long-term oral therapy with a
mixed ETA and ETB receptor antagonist prevents progres-
sive LV dysfunction and attenuates progressive LV chamber
remodeling in this dog model of moderate HF. The results
of the study clearly show that bosentan improves LV systolic
function and substantially alters the course of LV remodel-
ing. The beneficial effects of bosentan on LV remodeling are
shown by attenuation of 1) progressive LV chamber dila-
tion; 2) cardiomyocyte hypertrophy as evidenced by reduced
myocyte cross-sectional area; and 3) reduced reactive inter-
stitial fibrosis as evidenced by less accumulation of collagen
in the cardiac interstitium. Modulation of the remodeling
process by bosentan was accompanied by an increase in
cardiac index and a decrease in systemic vascular resistance
in the absence of changes in systemic blood pressure and in
the chronotropic state—features that have been deemed
desirable in the treatment of chronic HF in humans.
The fundamental observation of this study—namely, that
initiation of early treatment with an ET-1 antagonist
prevents the progression of LV dysfunction and ameliorates
LV chamber remodeling in dogs with moderate HF—is
supported by observations made in other animal models
(25,26,35,36) and in patients with HF (21,29,30,37). In rats
with large myocardial infarcts induced by coronary artery
ligation, eight-week treatment with bosentan improved
stroke volume index and prevented, in part, the rightward
shift of the pressure–volume curve as compared with rats
given placebo (25). In a Dahl salt-sensitive rat model of LV
hypertrophy and failure, long-term treatment with bosentan
as compared with placebo significantly attenuated the de-
crease in LV fractional shortening and the increase LV
systolic wall stress (35). In the same rat model, bosentan
significantly improved survival (35). Improved survival was
also observed in rats with HF secondary to myocardial
infarction treated long-term with bosentan (23) or with the
selective ETA receptor antagonist BQ-123 (25). In rabbits
with pacing-induced HF, Spinale et al. (26) showed that
concomitant three-week administration of a selective ETA
receptor antagonist significantly attenuated the decline in
LV fractional shortening and the increase in LV end-
diastolic dimension as compared with untreated control
animals. In patients with chronic HF and LVEF #30%,
intravenous bosentan reduced pulmonary artery wedge pres-
sure and systemic vascular resistance and increased cardiac
index as compared with patients receiving placebo (21,29).
Short-term administration of oral bosentan for two weeks in
patients with severe HF being treated with diuretics,
digoxin and angiotensin-converting enzyme inhibitors elic-
ited significant improvement in systemic and pulmonary
hemodynamic data, as evidenced by increased cardiac out-
put and a reduction in both pulmonary artery wedge
pressure and systemic vascular resistance (30).
In the present study, average cardiomyocyte cross-
sectional area, a measure of cardiomyocyte hypertrophy, was
significantly lower in dogs treated with bosentan than in
untreated control dogs. This finding is consistent with
studies in which ET has been shown to play a role in
stimulating cardiomyocyte hypertrophy (15–17). Exposure
of cultured rat neonatal cardiomyocytes to ET-1 for 6 h
resulted in cardiomyocyte hypertrophy associated with in-
creased expression of muscle-specific gene transcripts, in-
cluding myosin light chain 2 and alpha-actin (15). Studies
in cultured rat neonatal cardiomyocytes have also suggested
that endogenous ET-1, locally generated and secreted by
cardiomyocytes, may contribute to angiotensin II–induced
cardiac hypertrophy, possibly through an autocrine/
paracrine fashion (38). In this study, the angiotensin II–
induced protein synthesis was blocked by the ETA receptor
Figure 1. Bar graph depicting the mean (6SEM) LVEF in
untreated control dogs and in dogs treated with bosentan. Solid
bars indicate values obtained before initiating treatment (pretreat-
ment); hatched bars indicate values obtained after three months of
follow-up or active therapy (post-treatment). Probability values are
based on intragroup pretreatment to post-treatment comparisons.
Figure 2. Left, Bar graph depicting the mean (6SEM) LV
end-diastolic volume (EDV) in untreated control dogs (CON) and
in dogs treated with bosentan (BOS). Right, Bar graph depicting
the mean (6SEM) LV end-systolic volume (ESV) in untreated
control dogs and in dogs treated with bosentan. Solid bars indicate
values obtained before initiating treatment and hatched bars to
values obtained after three months of follow-up or active therapy.
Probability values are based on intragroup pretreatment to post-
treatment comparisons.
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antagonist BQ-123. Endothelin-1 has also been implicated
in the release of norepinephrine from adrenal chromaffin
cells (39) and in having a direct involvement in
norepinephrine-induced ventricular hypertrophy (40). In
the present study, treatment with bosentan blunted the rise
in plasma norepinephrine concentration observed in un-
treated dogs. Although the exact mechanism for this inter-
action is not known, the finding can explain, in part, the
attenuation of cardiomyocyte hypertrophy seen in dogs
treated with bosentan. Studies in rats with pressure overload
hypertrophy induced by aortic banding also showed that
blockade of endogenous ET-1 by BQ-123 prevented the
increase in LV weight to body weight ratio and in the
diameter of cardiomyocytes as compared with untreated rats
(16). Similarly, in rats with HF secondary to myocardial
infarction, long-term treatment with bosentan was shown to
attenuate LV hypertrophy assessed echocardiographically
(23). Not all studies in which ET-1 antagonists were in the
setting of HF have reported an amelioration of cardiac
hypertrophy (26,35,41). In rats surviving an acute myocar-
dial infarction for 24 h, four-week treatment with the ETA
receptor antagonist LU-135252 led to impaired scar heal-
ing, LV dilation and dysfunction (41). The authors con-
cluded that these negative findings may have been due, in
part, to the early use of ETA receptor antagonist after acute
myocardial infarction (41). In rabbits with HF induced by
rapid ventricular pacing, long-term treatment with an ETA
receptor antagonist had no effect on cardiomyocyte remod-
eling in terms of length or cross-sectional area (26). Treat-
ment with bosentan in Dahl salt-sensitive rats with pressure
overload cardiac hypertrophy and failure also failed to alter
the course of cardiac hypertrophy (35). The reasons for
these differences are not clear and may be, in part, model-
and species-dependent and perhaps due to differences in the
effects derived from the use of ETA-selective as compared
with mixed ET-1 antagonists. Nonetheless, additional stud-
ies may be needed to further examine the effects of ET
blockade on cardiac hypertrophy in the setting of HF.
It is well recognized that accumulation of collagen occurs
in the interstitium of the hypertrophied and failing heart, a
process termed “reactive interstitial fibrosis” (42,43). This
fibrous tissue response is thought to be responsible for
abnormal LV stiffness and systolic and diastolic function
(43) and has been implicated in the progression of HF (44).
In the present study, we observed a salutary effect of
bosentan on reactive interstitial fibrosis. Dogs treated with
bosentan had a significantly lower volume fraction of inter-
stitial collagen than untreated dogs. A reduction in cardiac
interstitial fibrosis was also reported in rats with HF
secondary to myocardial infarction after long-term treat-
ment with bosentan (23). The mechanism by which ET-1
Figure 3. Bar graph depicting the mean (6SEM) value of the
intragroup change (D) from pretreatment to post-treatment of LV
end-diastolic volume (EDV), end-systolic volume (ESV) and
ejection fraction (EF) in untreated control dogs (solid bars) and in
dogs treated with bosentan (hatched bars). Probability values are
based on comparisons of change between control and bosentan
(treatment effect).
Table 4. The Change Between Pretreatment and Post-treatment Hemodynamic, Angiographic and Plasma Norepinephrine Levels in
Control Dogs and Bosentan-Treated Dogs
Control
Group
Bosentan
Group
p Value
Repeated
Measures
Interaction
t Test
on
Changes
D HR (beats/min) 27 6 4 4 6 5 0.25 0.11
D Mean AoP (mm Hg) 1 6 4 21 6 3 0.59 0.64
D LV EDP (mm Hg) 0 6 1 23 6 2 0.21 0.21
D Peak 1dP/dt (mm Hg/s) 2236 6 87 100 6 111 0.10 0.04
D Peak 2dP/dt (mm Hg/s) 2219 6 119 493 6 191 0.037 0.008
D CI (liters/min per m2) 20.4 6 0.1 0.7 6 3 0.009 0.005
D SVR (dyneszszcm25) 907 6 521 2911 6 238 0.001 0.008
D LV EDV (ml) 13 6 6 24 6 2 0.08 0.02
D LV ESV (ml) 14 6 5 25 6 1 0.008 0.003
D LV EF (%) 26 6 1 5 6 2 0.003 0.001
D PNE (pg/ml) 118 6 28 221 6 59 0.023 0.05
Data are presented as the mean value 6 SEM.
D 5 change; other abbreviations as in Table 1.
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blockade elicits this beneficial effect is not known but may
involve the cardiac fibroblast, an active participant in the
remodeling process of several cardiac diseases (45,46).
Functionally active ETA and ETB receptors have been
reported to exist in fibroblasts (47). It is possible that the
increased release of ET-1 in HF can activate these recep-
tors, which, in turn, can promote synthesis and deposition
of collagen by cardiac fibroblasts. Endothelin-1 has also
been shown to affect collagen synthesis in cardiac fibroblasts
and reduce collagenase activity (18).
The mechanisms by which ET-1 receptor blockade elicits
its beneficial effects on LV function and remodeling in HF
are not fully understood. Some benefit is derived from
amelioration of cardiac hypertrophy and reactive interstitial
fibrosis. Elevated levels of ET-1 in HF can lead to vaso-
constriction and increased systemic vascular resistance. Re-
ceptor blockade can reverse this deleterious process with an
attendant reduction in systemic vascular resistance. Al-
though not measured in the present study, we have previ-
ously shown that plasma ET-1 level is elevated in this dog
model of HF, with further increases after administration of
bosentan, as expected (22). It is possible, however, that the
improvement in LV systolic function in HF with the use of
ET-1 antagonists may be independent of afterload reduc-
tion (35). Although ET-1 may elicit a positive inotropic
effect in normal myocardium, it has been shown to elicit a
negative inotropic effect in the presence of beta-adrenergic
stimulation (48), a response consistent with the pathophys-
iology of the HF. In cardiomyocytes isolated from rabbits
with pacing-induced HF treated with an ETA receptor
antagonist, Spinale et al. (26) demonstrated improvement in
indexes of contractile function, an observation consistent
with the findings of the present study. Other reported
effects of ET-1 may also lead to negative inotropic effects in
HF. Endothelin-1 can elicit negative inotropic effects on
the heart by reducing forskolin-induced increases of cyclic
adenosine monophosphate (49) or by decreasing Ca21
adenosine triphosphate messenger ribonucleic acid levels, or
both (50). Endothelin-1 may also have a direct cytotoxic
effect through degradation of phospholipids (51).
There are some limitations of the present study that
warrant consideration. A single dose of bosentan was used
on the basis of data generated in other mammalian species
as well as patients with HF. A dose-ranging study in dogs
with HF, and perhaps the use of both low- and high-dose
bosentan study arms, would have facilitated interpretation
of the efficacy of bosentan in this canine model of HF.
Another possible limitation of the study is the difficulty in
interpreting whether the benefits of bosentan on LV func-
tion and chamber remodeling were due to vasodilation alone
or instead to a specific antagonism of endothelin. This issue
could have been better resolved had the study contained
another monotherapy arm in which a vasodilator was used
that was less likely to impact LV performance and remod-
eling. In salt-sensitive hypertensive rats with HF, bosentan
prevented the progression of LV dysfunction, whereas the
alpha1-receptor antagonist doxazosin, a vasodilator, had no
effect, even though both compounds reduced afterload by
the same extent (35).
Conclusions. The results of this study indicate that early,
long-term monotherapy with bosentan prevents progressive
LV dysfunction and attenuates progressive LV chamber
remodeling in dogs with moderate HF. In addition to
improving cardiac hemodynamic variables and preserving
LV chamber size, treatment with bosentan also attenuated
cardiomyocyte hypertrophy and reduced cardiac interstitial
fibrosis. The study findings support the use of mixed ETA
and ETB receptor antagonists as adjuncts to the long-term
treatment of chronic HF.
Reprint requests and correspondence: Dr. Hani N. Sabbah,
Director, Cardiovascular Research, Henry Ford Hospital, 2799
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